Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ)
CNY 30.05
(0.0%)
CNY 30.05
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 422.71 Million | 385.76 Million | 370.44 Million | 368.48 Million | 414.86 Million | 402.4 Million |
| Cost of Revenue | 186.53 Million | 158.76 Million | 138.34 Million | 124.67 Million | 93.39 Million | 65.96 Million |
| Gross Profit | 236.17 Million | 226.99 Million | 232.09 Million | 243.81 Million | 321.46 Million | 336.43 Million |
| Operating Expenses | 531.67 Million | 447.52 Million | 295.12 Million | 230.88 Million | 307.45 Million | 321.75 Million |
| Selling, General and Administrative Expenses | 222.32 Million | 194.76 Million | 184.87 Million | 157.02 Million | 224.23 Million | 227.39 Million |
| Research and Development Expenses | 132.95 Million | 185.46 Million | 68.98 Million | 47.47 Million | 53.21 Million | 69.65 Million |
| Other Expenses | 92.23 Million | -3.12 Million | -1.2 Million | 188.16 Thousand | -397.37 Thousand | -290.94 Thousand |
| Cost and Expenses | 718.2 Million | 606.29 Million | 433.47 Million | 355.56 Million | 400.85 Million | 387.72 Million |
| Operating Income | -295.49 Million | -160.29 Million | -44.48 Million | 15.16 Million | 12.54 Million | 12.04 Million |
| Interest Expense | 35.02 Million | 10.59 Million | 9.12 Million | 8.94 Million | 7.48 Million | 1.15 Million |
| Income Tax Expense | 76.87 Million | -22.85 Million | -11.52 Million | -1.17 Million | -435.4 Thousand | -4.98 Million |
| Earnings before Tax | -298.02 Million | -163.42 Million | -45.69 Million | 15.34 Million | 12.14 Million | 11.75 Million |
| Net Income | -348.58 Million | -127.4 Million | -34.88 Million | 14.82 Million | 10.74 Million | 16.48 Million |
| Earnings Per Share Basic | -2.19 | -0.80 | -0.23 | 0.11 | 0.08 | 0.12 |
| Earnings Per Share Diluted | -2.19 | -0.80 | -0.23 | 0.11 | 0.08 | 0.12 |
| Weighted Average Shares Outstanding | 159.26 Million | 159.17 Million | 149.4 Million | 140 Million | 140 Million | 137.37 Million |
| Weighted Average Shares Outstanding (Diluted) | 159.26 Million | 159.17 Million | 149.4 Million | 140.38 Million | 140 Million | 137.37 Million |
| Gross Margin | 0.56 | 0.59 | 0.63 | 0.66 | 0.77 | 0.84 |
| EBIT Margin | -0.45 | -0.23 | 0.05 | 0.17 | 0.13 | 0.10 |
| Profit Margin | -0.82 | -0.33 | -0.09 | 0.04 | 0.03 | 0.04 |
| EBITDA | -190.85 Million | -94.23 Million | 15.41 Million | 49.98 Million | 53.97 Million | 40.89 Million |
| Earnings Before Tax Margin | -0.70 | -0.42 | -0.12 | 0.04 | 0.03 | 0.03 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 108.13 Million | 98.13 Million | 117.81 Million | 143.02 Million | 422.71 Million | 102.2 Million |
| Cost of Revenue | 42.26 Million | 36.16 Million | 48.42 Million | 63.83 Million | 180.04 Million | 41.37 Million |
| Gross Profit | 65.86 Million | 61.96 Million | 69.39 Million | 79.19 Million | 242.66 Million | 60.82 Million |
| Operating Expenses | 87.51 Million | 71.03 Million | 77.1 Million | 130.99 Million | 437.21 Million | 85.36 Million |
| Selling, General and Administrative Expenses | 146.33 Million | 32.16 Million | 69.35 Million | 9.49 Million | - | 111.64 Million |
| Research and Development Expenses | 8.49 Million | 7.15 Million | 7.21 Million | 40.69 Million | - | 13.31 Million |
| Other Expenses | -67.31 Million | -91.01 Thousand | -538.05 Thousand | -932.97 Thousand | -2.53 Million | -755.66 Thousand |
| Cost and Expenses | 129.78 Million | 107.2 Million | 125.53 Million | 194.82 Million | 617.26 Million | 126.73 Million |
| Operating Income | -33.96 Million | -19.12 Million | -7.71 Million | -109.43 Million | -295.49 Million | -38.59 Million |
| Interest Expense | 8.7 Million | 8.72 Million | 9.16 Million | 9.29 Million | 35.02 Million | 9.28 Million |
| Income Tax Expense | 2.03 Million | 2.19 Million | -264.84 Thousand | 52.67 Million | 76.87 Million | 1.23 Million |
| Earnings before Tax | -35.59 Million | -19.21 Million | -13.32 Million | -110.36 Million | -298.02 Million | -39.35 Million |
| Net Income | -34.6 Million | -21.39 Million | -14.64 Million | -152.76 Million | -348.58 Million | -38.61 Million |
| Earnings Per Share Basic | -0.22 | -0.13 | -0.09 | -0.96 | - | -0.24 |
| Earnings Per Share Diluted | -0.22 | -0.13 | -0.09 | -0.96 | - | -0.24 |
| Weighted Average Shares Outstanding | 159.26 Million | 159.26 Million | 159.26 Million | 159.25 Million | 159.26 Million | 159.26 Million |
| Weighted Average Shares Outstanding (Diluted) | 159.26 Million | 159.26 Million | 159.26 Million | 159.25 Million | 159.26 Million | 159.26 Million |
| Gross Margin | 0.61 | 0.63 | 0.59 | 0.55 | 0.57 | 0.60 |
| EBIT Margin | -0.25 | -0.09 | -0.04 | -0.68 | - | -0.28 |
| Profit Margin | -0.32 | -0.22 | -0.12 | -1.07 | -0.82 | -0.38 |
| EBITDA | -26.89 Million | -9.11 Million | -5.2 Million | -97.26 Million | - | -29.06 Million |
| Earnings Before Tax Margin | -0.31 | -0.19 | -0.07 | -0.77 | -0.70 | -0.38 |
1309
KARNEL-B
SSBI
ENOG
XELTB
9332